Clinical trials: sponsored by Arrowhead Pharmaceuticals

Homozygous Familial Hypercholesterolemia

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

• Terminated
• Age: 16 years and older
• Phase 2
• Injection or infusion
• Results posted

Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks.

Trial name

Gateway (NCT05217667)

Testing

ARO-ANG 3 Injection

Where

7 sites in United States, Australia and 2 more

Volunteers

18 people

Sponsor

Arrowhead Pharmaceuticals